JOP20190115B1 - مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp) - Google Patents
مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp)Info
- Publication number
- JOP20190115B1 JOP20190115B1 JOP/2019/0115A JOP20190115A JOP20190115B1 JO P20190115 B1 JOP20190115 B1 JO P20190115B1 JO P20190115 A JOP20190115 A JO P20190115A JO P20190115 B1 JOP20190115 B1 JO P20190115B1
- Authority
- JO
- Jordan
- Prior art keywords
- parp
- poly
- inhibitors
- ribose polymerase
- adp ribose
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
يتعلق الاختراع الحالي بتركيبة صيدلانية مشتملة على مادة حاملة أو مادة مخفِّفة مقبولة صيدلانياً ومركب ممثل بواسطة الصيغة البنائية التالية:
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662440581P | 2016-12-30 | 2016-12-30 | |
| PCT/US2017/068636 WO2018125961A1 (en) | 2016-12-30 | 2017-12-28 | Poly-adp ribose polymerase (parp) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JOP20190115A1 JOP20190115A1 (ar) | 2019-05-20 |
| JOP20190115B1 true JOP20190115B1 (ar) | 2023-09-17 |
Family
ID=61007849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2019/0115A JOP20190115B1 (ar) | 2016-12-30 | 2017-12-28 | مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp) |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US11034670B2 (ar) |
| EP (1) | EP3562822B1 (ar) |
| JP (1) | JP7141399B2 (ar) |
| KR (1) | KR102606799B1 (ar) |
| CN (1) | CN110167926B (ar) |
| AR (1) | AR110706A1 (ar) |
| AU (1) | AU2017388376B2 (ar) |
| BR (1) | BR112019011676A2 (ar) |
| CA (1) | CA3047137A1 (ar) |
| CO (1) | CO2019007906A2 (ar) |
| CY (1) | CY1124565T1 (ar) |
| DK (1) | DK3562822T3 (ar) |
| EA (1) | EA201991412A1 (ar) |
| ES (1) | ES2875841T3 (ar) |
| HR (1) | HRP20210887T1 (ar) |
| HU (1) | HUE054382T2 (ar) |
| IL (1) | IL267676B (ar) |
| JO (1) | JOP20190115B1 (ar) |
| LT (1) | LT3562822T (ar) |
| MA (1) | MA47165B1 (ar) |
| MD (1) | MD3562822T2 (ar) |
| MX (1) | MX2019007870A (ar) |
| PH (1) | PH12019501529A1 (ar) |
| PL (1) | PL3562822T3 (ar) |
| PT (1) | PT3562822T (ar) |
| RS (1) | RS61895B1 (ar) |
| SA (1) | SA519401894B1 (ar) |
| SI (1) | SI3562822T1 (ar) |
| TW (1) | TWI773718B (ar) |
| UA (1) | UA124777C2 (ar) |
| WO (1) | WO2018125961A1 (ar) |
| ZA (2) | ZA201904004B (ar) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3359528B1 (en) * | 2015-10-07 | 2022-01-12 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| MD3562822T2 (ro) * | 2016-12-30 | 2021-07-31 | Mitobridge Inc | Inhibitori de poli-ADP riboză polimerază (PARP) |
| BR112022008282A2 (pt) * | 2019-10-30 | 2022-07-26 | Digmbio Inc | Derivados de isoquinolinona, método para preparar os mesmos e composição farmacêutica para prevenir ou tratar doenças relacionadas à poli(adp-ribose) polimerase-1, que compreendem os mesmos como ingrediente ativo |
| CN118076585A (zh) * | 2021-07-23 | 2024-05-24 | 国家医疗保健研究所 | 革兰氏阴性菌外排泵抑制剂 |
| CN113603630B (zh) * | 2021-08-10 | 2023-06-27 | 苏州小栗医药科技有限公司 | 一种4-苯基哌啶盐酸盐的合成方法 |
| WO2024061768A1 (en) | 2022-09-19 | 2024-03-28 | Basf Se | Azole pesticidal compounds |
| CN118084678B (zh) * | 2024-03-01 | 2024-09-06 | 长沙唯楚医药科技有限公司 | 一种2-溴-6-氟苯胺的制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001070737A2 (en) | 2000-03-20 | 2001-09-27 | Sepracor, Inc. | Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof |
| ATE402704T1 (de) | 2000-03-27 | 2008-08-15 | Abbott Gmbh & Co Kg | Dopamin-d3-rezeptor-liganden zur behandlung von sucht |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| CN1922171B (zh) | 2004-02-26 | 2012-10-17 | Aska制药株式会社 | 嘧啶衍生物 |
| EP1760071A4 (en) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
| NZ551680A (en) * | 2004-06-30 | 2010-02-26 | Janssen Pharmaceutica Nv | Quinazolinone derivatives as PARP inhibitors |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| MX2008000745A (es) | 2005-07-15 | 2008-03-14 | Schering Corp | Derivados de quinazolina utiles en el tratamiento del cancer. |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| WO2007110868A2 (en) | 2006-03-28 | 2007-10-04 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| EP2697206B1 (en) | 2011-04-10 | 2019-04-03 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| CN102838600A (zh) | 2011-06-24 | 2012-12-26 | 山东亨利医药科技有限责任公司 | 苯基喹唑啉类PI3Kδ抑制剂 |
| US9505749B2 (en) * | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| RU2669393C2 (ru) | 2013-07-31 | 2018-10-11 | Мерк Патент Гмбх | Оксохиназолинилбутанамидные производные |
| BR112016025396A2 (pt) | 2014-05-07 | 2017-08-15 | Merck Patent Gmbh | derivados de heterociclil-butanamida |
| CN105924434A (zh) * | 2015-02-28 | 2016-09-07 | 广东东阳光药业有限公司 | 取代的氨基嘧啶类化合物及其使用方法和用途 |
| WO2018026371A1 (en) | 2016-08-04 | 2018-02-08 | Sunovion Pharmaceuticals Inc. | Dual nav1.2/5ht2a inhibitors for treating cns disorders |
| MD3562822T2 (ro) * | 2016-12-30 | 2021-07-31 | Mitobridge Inc | Inhibitori de poli-ADP riboză polimerază (PARP) |
-
2017
- 2017-12-28 MD MDE20191268T patent/MD3562822T2/ro unknown
- 2017-12-28 CN CN201780082024.8A patent/CN110167926B/zh active Active
- 2017-12-28 CA CA3047137A patent/CA3047137A1/en active Pending
- 2017-12-28 JO JOP/2019/0115A patent/JOP20190115B1/ar active
- 2017-12-28 MX MX2019007870A patent/MX2019007870A/es unknown
- 2017-12-28 UA UAA201908940A patent/UA124777C2/uk unknown
- 2017-12-28 DK DK17832694.8T patent/DK3562822T3/da active
- 2017-12-28 JP JP2019535356A patent/JP7141399B2/ja active Active
- 2017-12-28 LT LTEP17832694.8T patent/LT3562822T/lt unknown
- 2017-12-28 RS RS20210653A patent/RS61895B1/sr unknown
- 2017-12-28 US US16/473,127 patent/US11034670B2/en active Active
- 2017-12-28 AU AU2017388376A patent/AU2017388376B2/en active Active
- 2017-12-28 EA EA201991412A patent/EA201991412A1/ru unknown
- 2017-12-28 EP EP17832694.8A patent/EP3562822B1/en active Active
- 2017-12-28 SI SI201730772T patent/SI3562822T1/sl unknown
- 2017-12-28 PL PL17832694T patent/PL3562822T3/pl unknown
- 2017-12-28 WO PCT/US2017/068636 patent/WO2018125961A1/en active Search and Examination
- 2017-12-28 KR KR1020197021891A patent/KR102606799B1/ko active IP Right Grant
- 2017-12-28 ES ES17832694T patent/ES2875841T3/es active Active
- 2017-12-28 BR BR112019011676A patent/BR112019011676A2/pt unknown
- 2017-12-28 PT PT178326948T patent/PT3562822T/pt unknown
- 2017-12-28 HU HUE17832694A patent/HUE054382T2/hu unknown
- 2017-12-28 MA MA47165A patent/MA47165B1/fr unknown
- 2017-12-29 AR ARP170103718A patent/AR110706A1/es unknown
- 2017-12-29 TW TW106146555A patent/TWI773718B/zh active
-
2019
- 2019-05-29 SA SA519401894A patent/SA519401894B1/ar unknown
- 2019-06-20 ZA ZA2019/04004A patent/ZA201904004B/en unknown
- 2019-06-26 IL IL267676A patent/IL267676B/en unknown
- 2019-06-28 PH PH12019501529A patent/PH12019501529A1/en unknown
- 2019-07-23 CO CONC2019/0007906A patent/CO2019007906A2/es unknown
-
2020
- 2020-06-03 ZA ZA2020/03310A patent/ZA202003310B/en unknown
-
2021
- 2021-06-04 HR HRP20210887TT patent/HRP20210887T1/hr unknown
- 2021-06-08 CY CY20211100500T patent/CY1124565T1/el unknown
- 2021-06-09 US US17/342,873 patent/US11993585B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501529A1 (en) | Poly-adp ribose polymerase (parp) inhibitors | |
| NI201800093A (es) | Inhibidores de mcl1 macrocíclicos para tratar el cáncer | |
| PH12017501016B1 (en) | Triazolopyrimidine compounds and uses thereof | |
| SA518400547B1 (ar) | مشتقات بيرازولو بيريميدين كمثبط كيناز | |
| PH12017501326A1 (en) | Tgf-� inhibitors | |
| PH12018500360A1 (en) | Heteroaryl derivatives as parp inhibitors | |
| TN2020000125A1 (en) | Amino-fluoropiperidine derivative as kinase inhibitor | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
| TN2020000081A1 (en) | Amino-methyl piperidine derivative as kinase inhibitor | |
| PH12019501198A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
| EA201490724A1 (ru) | Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia | |
| SA520412335B1 (ar) | مشتقات أوكسي فلورو ببريدين كمثبط كيناز | |
| TN2017000134A1 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
| MX2018008095A (es) | Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih. | |
| NZ746906A (en) | Oxaborole esters and uses thereof | |
| CO2019007836A2 (es) | Derivados de pirrolotriazina como inhibidor de cinasas |